Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02440464 · ClinicalTrials.gov registry record · Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

A Phase 2 study of Multiple Myeloma, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
Phase 2
Development phase
57
Enrollment target
15
Study locations

NCT02440464: Completed Phase 2 study of Multiple Myeloma, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT02440464 is a Phase 2 study of Multiple Myeloma that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 57 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02440464, a Phase 2 study of Multiple Myeloma, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
Phase 2
Development phase
57 participants
Enrollment target
15
Study locations

Study Summary

This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma". It is hypothesized that Ixazomib maintenance therapy will result in improved PFS in patients with high-risk multiple myeloma following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) compared to placebo.

Primary Outcome

The primary endpoint compares progression-free survival as a time to event endpoint from randomization between patients randomized to ixazomib and placebo maintenance in high risk multiple myeloma. Participants are considered a failure of the primary endpoint if they die or suffer from disease progression or if they initiate non-protocol anti-myeloma therapy. Disease progression was evaluated using the International Uniform Response Criteria. Participants must meet one of the criteria for diseas

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Fludarabine
  • DRUG Melphalan
  • DRUG Bortezomib
  • PROCEDURE Allogeneic HSCT
  • DRUG Ixazomib

Study Locations (15)

Georgia

  • Emory University - Atlanta
  • BMT Northside - Atlanta

Wisconsin

  • University of Wisconsin Hospital & Clinics - Madison
  • Medical College of Wisconsin - Milwaukee

Alabama

  • University of Alabama - Birmingham

California

  • City of Hope National Medical Center - Duarte

Florida

  • H. Lee Moffitt Cancer Center - Tampa

Illinois

  • Loyola University Medical Center - Maywood

Kentucky

  • University of Kentucky - Lexington

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2015-08
Est. Completion 2020-10-01
Phase Phase 2
National Heart, Lung, and Blood Institute (NHLBI)

501 total trials

What the finished NCT02440464 record still lists

NCT02440464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT02440464 lists 15 locations in 13 states (Georgia, Wisconsin, Alabama).

Frequently Asked Questions

What is clinical trial NCT02440464 about?

NCT02440464 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)". This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Mul...

What is the current status of trial NCT02440464?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2015-08. Estimated completion is 2020-10-01.

What conditions does trial NCT02440464 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02440464?

The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Bortezomib (DRUG), Allogeneic HSCT (PROCEDURE), Ixazomib (DRUG).

Who is sponsoring clinical trial NCT02440464?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02440464 being conducted?

This trial has 15 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02440464's enrollment target sits among peer trials

57 235th of 438 higher than 201 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02440464, the US trial registry maintained by the National Library of Medicine. NCT02440464 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.